Nanomedicine promotes ferroptosis to inhibit tumour proliferation in vivo

Yifeng Luo,Gang Niu,Hui Yi,Qingling Li,Zhiqiang Wu,Jing Wang,Juan Yang,Bo Li,Yuan Peng,Ying Liang,Weiwei Wang,Zhenwei Peng,Xintao Shuai,Yu Guo
DOI: https://doi.org/10.1016/j.redox.2021.101908
IF: 11.4
2021-06-01
Redox Biology
Abstract:<p>miR-101-3p may play a therapeutic role in various tumours. However, its anti-tumour mechanism remains unclear, and a definitive strategy to treat tumour cells <em>in vivo</em> is lacking. The objective of this study was to investigate the inhibitory mechanism of miR-101-3p on tumour cells and to develop relevant nanomedicines for <em>in vivo</em> therapy. The expression levels of miR-101-3p and its target protein TBLR1 in lung cancer (LC) tissues and cells were detected, and their relationship with ferroptosis clarified. Furthermore, the efficacy of nanocarriers in achieving <em>in vivo</em> therapeutic gene delivery was evaluated. Nanomedicine was further developed, with the anti-proliferative <em>in vivo</em> therapeutic effect validated using a subcutaneous xenograft cancer model. In LC tissues, the level of miR-101-3p negatively correlated with tumour size and TNM stage. miR-101-3p restores ferroptosis in tumour cells by directly targeting TBLR1, which in turn promotes apoptosis and inhibits cell proliferation. We developed nanomedicine that can deliver miR-101-3p to tumour cells <em>in vivo</em> to achieve ferroptosis recovery, as well as to inhibit <em>in vivo</em> tumour proliferation. The miR-101-3p/TBLR1 axis plays an important role in lung cancer ferroptosis. Nanopharmaceuticals that increase miR-101-3p levels may be effective therapies to inhibit tumour proliferation.</p>
biochemistry & molecular biology
What problem does this paper attempt to address?